- Home
- NBIX
as of 11-28-2025 12:36pm EST
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 14.4B | IPO Year: | 1996 |
| Target Price: | $172.33 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 4.19 | EPS Growth: | 12.44 |
| 52 Week Low/High: | $84.23 - $157.67 | Next Earning Date: | 10-28-2025 |
| Revenue: | $2,682,700,000 | Revenue Growth: | 19.61% |
| Revenue Growth (this year): | 23.68% | Revenue Growth (next year): | 18.02% |
AI-Powered NBIX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Neurocrine Biosciences Inc. (NBIX)
Director
Avg Cost/Share
$143.37
Shares
15,000
Total Value
$2,150,512.50
Owned After
7,068
SEC Form 4
Director
Avg Cost/Share
$151.82
Shares
18,000
Total Value
$2,732,689.80
Owned After
40,360
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| MORROW GEORGE J | NBIX | Director | Nov 25, 2025 | Sell | $143.37 | 15,000 | $2,150,512.50 | 7,068 | |
| RASTETTER WILLIAM H | NBIX | Director | Nov 5, 2025 | Sell | $151.82 | 18,000 | $2,732,689.80 | 40,360 | |
| Gano Kyle | NBIX | Chief Executive Officer | Nov 4, 2025 | Sell | $141.97 | 300 | $42,591.00 | 140,407 |
Compare NBIX vs Leading Stocks
See how NBIX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NBIX Neurocrine Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.